AU2014326257B2 - Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins - Google Patents

Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins Download PDF

Info

Publication number
AU2014326257B2
AU2014326257B2 AU2014326257A AU2014326257A AU2014326257B2 AU 2014326257 B2 AU2014326257 B2 AU 2014326257B2 AU 2014326257 A AU2014326257 A AU 2014326257A AU 2014326257 A AU2014326257 A AU 2014326257A AU 2014326257 B2 AU2014326257 B2 AU 2014326257B2
Authority
AU
Australia
Prior art keywords
fxa variant
seq
protein
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014326257A
Other languages
English (en)
Other versions
AU2014326257A1 (en
Inventor
Michael Anthony JANKOWSKI
Keith A. Johnson
Wendy Carol PIACENZA
Jason C. ROUSE
Michael Shamashkin
Penelope Jane SHARPE
Mary Beth Switzer
Stacey B. WESTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2014326257A1 publication Critical patent/AU2014326257A1/en
Application granted granted Critical
Publication of AU2014326257B2 publication Critical patent/AU2014326257B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
AU2014326257A 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins Ceased AU2014326257B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
US61/881,834 2013-09-24
PCT/IB2014/064564 WO2015044836A1 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Publications (2)

Publication Number Publication Date
AU2014326257A1 AU2014326257A1 (en) 2016-03-10
AU2014326257B2 true AU2014326257B2 (en) 2017-08-10

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014326257A Ceased AU2014326257B2 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins

Country Status (19)

Country Link
US (3) US9757434B2 (cg-RX-API-DMAC7.html)
EP (1) EP3049434A1 (cg-RX-API-DMAC7.html)
JP (1) JP6429885B2 (cg-RX-API-DMAC7.html)
KR (1) KR101988705B1 (cg-RX-API-DMAC7.html)
CN (2) CN105579468A (cg-RX-API-DMAC7.html)
AR (1) AR097732A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014326257B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016005899A8 (cg-RX-API-DMAC7.html)
CA (1) CA2924981C (cg-RX-API-DMAC7.html)
HK (1) HK1218760A1 (cg-RX-API-DMAC7.html)
IL (2) IL244258A0 (cg-RX-API-DMAC7.html)
MX (1) MX373466B (cg-RX-API-DMAC7.html)
MY (1) MY173548A (cg-RX-API-DMAC7.html)
PE (1) PE20160877A1 (cg-RX-API-DMAC7.html)
RU (1) RU2648144C2 (cg-RX-API-DMAC7.html)
SA (1) SA516370751B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201601221XA (cg-RX-API-DMAC7.html)
TW (1) TWI631134B (cg-RX-API-DMAC7.html)
WO (1) WO2015044836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
PE20190661A1 (es) * 2016-06-17 2019-05-08 Portola Pharm Inc Preparacion de derivados del factor xa
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175931A1 (en) * 2005-11-15 2009-07-09 Camire Rodney M Compositions and methods for modulating hemostasis
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
JP2008509688A (ja) * 2004-08-17 2008-04-03 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変ビタミンｋ依存性ポリペプチド
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
DK2915564T3 (da) * 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
AU2009264282B2 (en) 2008-06-24 2013-04-18 Octapharma Ag A process of purifying coagulation factor VIII
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
US8436144B2 (en) 2008-12-19 2013-05-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
EP2453910B1 (en) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
EA201291482A1 (ru) * 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
AU2014326257B2 (en) 2013-09-24 2017-08-10 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins
CA2928762A1 (en) 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
MX375355B (es) 2014-01-24 2025-03-04 Pfizer Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175931A1 (en) * 2005-11-15 2009-07-09 Camire Rodney M Compositions and methods for modulating hemostasis
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUNCE, M.W. et al.: "Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro", BLOOD (2011), Vol.117 No.1 pg290-298 *
IVANCIU, L. et al.: "A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia", NATURE BIOTECHNOLOGY (2011), Vol. 29 No.11 pages 1028-1033 *
YAN-MEI SUN, et al.: "Vitamin K epoxide reductase significantly improves carboxylation in a cell line overexpressing factor X", BLOOD (2005), Vol.106 No.12 pg 3811-3815 *

Also Published As

Publication number Publication date
BR112016005899A8 (pt) 2018-02-06
KR20160044034A (ko) 2016-04-22
CN105579468A (zh) 2016-05-11
US20150182604A1 (en) 2015-07-02
TWI631134B (zh) 2018-08-01
AU2014326257A1 (en) 2016-03-10
IL244258A0 (en) 2016-04-21
BR112016005899A2 (pt) 2017-09-26
TW201524996A (zh) 2015-07-01
JP6429885B2 (ja) 2018-11-28
KR101988705B1 (ko) 2019-06-12
EP3049434A1 (en) 2016-08-03
CA2924981A1 (en) 2015-04-02
WO2015044836A1 (en) 2015-04-02
US20170333535A1 (en) 2017-11-23
MX2016003871A (es) 2016-08-04
RU2648144C2 (ru) 2018-03-22
IL279396A (en) 2021-01-31
PE20160877A1 (es) 2016-09-11
MX373466B (es) 2020-05-25
CA2924981C (en) 2020-03-31
MY173548A (en) 2020-02-04
RU2016108608A (ru) 2017-10-26
CN112195169A (zh) 2021-01-08
SG11201601221XA (en) 2016-04-28
US20210106658A1 (en) 2021-04-15
AR097732A1 (es) 2016-04-13
HK1218760A1 (zh) 2017-03-10
JP2016535071A (ja) 2016-11-10
US9757434B2 (en) 2017-09-12
US10660946B2 (en) 2020-05-26
SA516370751B1 (ar) 2018-04-05

Similar Documents

Publication Publication Date Title
US20210106658A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EP2108045B1 (en) Improved fix-mutant proteins for hemophilia b treatment
US9388402B2 (en) Method for improved isolation of recombinantly produced proteins
US20250230426A1 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP2108046B1 (en) Fviii-independent fix-mutant proteins for hemophilia a treatment
AU2014202989B2 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
US20190264188A1 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
JP5722314B2 (ja) 高純度可溶性トロンボモジュリン及びその製造方法
HK40007078A (en) Method for isolation of recombinantly produced proteins
WO2017025566A1 (en) Improved recombinant factor vii
AU2016238889A1 (en) Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
HK1178048A (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
HK1151184A1 (zh) 重组纤维蛋白原
KR20060104553A (ko) 항혈전 항체의 정제방법

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired